Sustainable Manufacturing of <i>trans</i>-4-Trifluoromethyl-<scp>l</scp>-proline via Stereochemical Editing: A Combined In Silico and Experimental Approach-Reference-Cited by-同舟云学术

Sustainable Manufacturing of trans-4-Trifluoromethyl-l-proline via Stereochemical Editing: A Combined In Silico and Experimental Approach

Published:2024-07-31 Issue: Volume: Page:
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Algera Russell F.¹,Allais Christophe¹^ORCID,Cabrera Pablo J.¹,González-Esguevillas María¹,Guan Yanfei¹^ORCID,James Chintelle¹,Lee Johnny W.¹^ORCID,Massicott Jeffrey M.²,McInturff Emma L.¹^ORCID,Pearson Robert J.¹,Risley Hud¹,Watson Rebecca B.¹

Affiliation:

1. Pfizer Chemical Research and Development, Pfizer Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States

2. Pfizer Analytical Research and Development, Pfizer Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.4c00202

Reference22 articles.

1. Allerton, C. M. N.; Arcari, J. T.; Aschenbrenner, L. M.; Avery, M.; Bechle, B. M.; Behzadi, M. A.; Boras, B.; Buzon, L. M.; Cardin, R. D.; Catlin, N. R. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 J. Med. Chem. 2024 10.1021/acs.jmedchem.3c02469.

2. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

3. Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months

4. Synthesis of Nirmatrelvir: Development of Magnesium Sulfate-Mediated Aminolysis for the Manufacture of the Eastern Fragment

5. Stereochemical Editing via Coupled Epimerization and Optical Resolution to Sustainably Manufacture a Key Adagrasib Building Block